Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research

Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972.ABSTRACTAccording to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and ...
Source: World Psychiatry - May 7, 2022 Category: Psychiatry Authors: Giovanni Ostuzzi Federico Bertolini Federico Tedeschi Giovanni Vita Paolo Brambilla Lorenzo Del Fabro Chiara Gastaldon Davide Papola Marianna Purgato Guido Nosari Cinzia Del Giovane Christoph U Correll Corrado Barbui Source Type: research